Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592382 | 0.84 | TDP1 (0.63) | NPSR1TDP1POLBMAPTL3MBTL1 | |
| SCHEMBL10651224 | 0.84 | TDP1 (0.46) | TDP1ATMMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL6887172 | 0.83 | NPSR1 (0.50) | NPSR1TDP1POLBARGAA | |
| SCHEMBL30484019 | 0.83 | NPSR1 (0.50) | NPSR1TDP1POLBARGAA | |
| SCHEMBL10649330 | 0.82 | TDP1 (0.45) | TDP1ATMMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL6882245 | 0.82 | NPSR1 (0.49) | NPSR1TDP1POLBATMMAPT | |
| SCHEMBL6072565 | 0.80 | VCAM1 (0.48) | NPSR1TDP1POLBMAPTGAA | |
| SCHEMBL4009144 | 0.79 | NPSR1 (0.77) | NPSR1TDP1POLBMAPTALDH1A1 | |
| SCHEMBL15356395 | 0.78 | TDP1 (0.53) | TDP1ATMMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL9196616 | 0.78 | ALDH1A1 (0.51) | NPSR1TDP1ATMMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101522668-B | Oxyindole derivatives as 5ht4 receptor agonists | PFIZER | 2012-06-06 | — | — | CN | disclosed |
| EP-1856110-B1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100173925-A1 | OXYINDOLE DERIVATIVES | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-7589109-B2 | Oxyindole derivatives | PFIZER INC (US) | 2009-09-15 | — | — | US | disclosed |
| CN-101522668-A | Oxyindole derivatives as 5ht4 receptor agonists | PFIZER JAPAN INC (US) | 2009-09-02 | — | — | CN | disclosed |
| EP-1856110-A1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | Pfizer, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060194842-A1 | Oxyindole derivatives | PFIZER INC. | 2006-08-31 | — | — | US | disclosed |
| WO-2006090279-A1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER JAPAN INC. (JP) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173925-A1 | OXYINDOLE DERIVATIVES | HTR4, HTR5A, HRH4 | NPSR1 24/4885TDP1 2496/4885POLB 4788/4885 |
| US-20060194842-A1 | Oxyindole derivatives | HTR4, HTR5A, HRH4 | NPSR1 24/4885TDP1 2496/4885POLB 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.